Epidermal growth factor receptor‑targeted antibody nimotuzumab combined with chemoradiotherapy improves survival in patients with locally advanced head and neck squamous cell carcinoma: a propensity score matching real‐world study

Epidermal growth factor receptor‑targeted antibody nimotuzumab combined with chemoradiotherapy improves survival in patients with locally advanced head and neck squamous cell carcinoma: a propensity score matching real‐world study

Abstract Patients with locally advanced head and neck squamous cell carcinoma (LA‐HNSCC) have poor survival outcomes. The real‐world efficacy of nimotuzumab plus intensity modulated radiotherapy (IMRT)‐based chemoradiotherapy in patients with LA‐HNSCC remains unclear. A total of 25,442 HNSCC patient...

Full description

Bibliographic Details
Main Authors: Peng Zhang, Xinxin Zhang, Jinyi Lang, Shaoxiong Wu, Yan Sun, Peiguo Wang, Sufang Qiu, Xiaodong Huang, Guoxin Ren, Kun Liu, Xiaojing Du, Shaowen Xiao, Zhongqiu Wang, Youliang Weng, Ye Zhang, Hang Zhou, Wenyong Tu, Chenping Zhang, Junlin Yi
Format: Article
Language:English
Published: Wiley 2024-07-01
Series:MedComm
Subjects:
chemoradiotherapy
IMRT
LA‐HNSCC
nimotuzumab
safety
survival benefits
Online Access:https://doi.org/10.1002/mco2.608

Internet

https://doi.org/10.1002/mco2.608

Similar Items